Immunetrics is a leading brand in the field of model-informed drug development and decision-making. With a team of expert biologists, they offer a range of services and solutions to enhance the drug development process. Their modeling services include novel target evaluation, dose optimization, phase 3 go/no-go analysis, and combinatorial drug approaches.

By incorporating data from in vitro and animal studies to human clinical trials, Immunetrics generates diverse virtual patient populations for realistic predictions. A key offering from Immunetrics is their advanced model development platform called Thales. This platform automates and streamlines the QSP modeling process, allowing users to quickly generate virtual patient populations and refine model design.

Thales utilizes AI and machine learning to fundamentally change the way models are developed, making it a powerful tool in drug development. Immunetrics has a proven track record of success, having contributed to the design of numerous phase II/III clinical trials and successfully predicting trial outcomes. Their QSP modeling services and software are customizable and cost-effective, offering researchers a valuable resource to propel their research forward.

Contact Immunetrics today to find out how they can assist you in your drug development journey